Andersson BS - Search Results

1

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Bashir Q, et al. Among authors: andersson bs. Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22. Lancet Haematol. 2019. PMID: 30910541 Free PMC article. Clinical Trial.

2

High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.

van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, et al. van Besien K, et al. Bone Marrow Transplant. 1995 Apr;15(4):549-55. Bone Marrow Transplant. 1995. PMID: 7655380

3

High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.

Kantarjian HM, Talpaz M, Andersson B, Khouri I, Giralt S, Rios MB, Champlin R, Hester J, Deisseroth AB. Kantarjian HM, et al. Bone Marrow Transplant. 1994 Jul;14(1):57-61. Bone Marrow Transplant. 1994. PMID: 7951120 Clinical Trial.

4

A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.

Przepiorka D, Ippoliti C, Giralt S, van Beisen K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, et al. Przepiorka D, et al. Bone Marrow Transplant. 1994 Sep;14(3):449-53. Bone Marrow Transplant. 1994. PMID: 7994271 Clinical Trial.

5

Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.

Ippoliti C, Przepiorka D, Giralt S, Andersson BS, Wallerstein RO, Gutterman J, Deisseroth AB, Champlin RE. Ippoliti C, et al. Among authors: andersson bs. Bone Marrow Transplant. 1993 Jan;11(1):55-9. Bone Marrow Transplant. 1993. PMID: 8094309

6

Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.

Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, et al. Dimopoulos MA, et al. Blood. 1993 Oct 15;82(8):2324-8. Blood. 1993. PMID: 8104539 Free article. Clinical Trial.

7

Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304.

Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM, O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GP. Anaissie EJ, et al. Among authors: andersson bs. Clin Infect Dis. 1993 Dec;17(6):1022-31. doi: 10.1093/clinids/17.6.1022. Clin Infect Dis. 1993. PMID: 8110925 Clinical Trial.

8

Adverse effects of molgramostim in marrow transplant recipients.

Ippoliti C, Przepiorka D, Smith T, Maiese S, Giralt S, Andersson BS, Deisseroth AB, Champlin RE. Ippoliti C, et al. Among authors: andersson bs. Clin Pharm. 1993 Jul;12(7):520-5. Clin Pharm. 1993. PMID: 8354039 No abstract available.

9

Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine.

Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Andersson B, Claxton D. Deisseroth AB, et al. Hum Gene Ther. 1993 Feb;4(1):71-85. doi: 10.1089/hum.1993.4.1-71. Hum Gene Ther. 1993. PMID: 8461383 Clinical Trial. No abstract available.

10

Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.

Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin RE. Giralt SA, et al. Among authors: andersson bs. J Clin Oncol. 1993 Jun;11(6):1055-61. doi: 10.1200/JCO.1993.11.6.1055. J Clin Oncol. 1993. PMID: 8501491

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

288 results

Search Page

Filters